3-Hydroxyanthranilic acid is an aminobenzoic acid commonly used as an intermediate in various chemical reactions.[1]
Application
<ul> <li><strong>Direct enzyme inhibition to mitigate quinolinic acid formation:</strong> Used to synthesize 2-amino-3-carboxymuconic semialdehyde (ACMS) during the kynurenine pathway of Tryptophan catabolism (Sanz et al., 2022).</li> </ul>
Sorafenib is the FDA-approved first-line target drug for HCC patients. However, sorafenib only confers 3-5 months of survival benefit with <30% of HCC patients. Thus, it is necessary to develop a sensitizer for hepatocellular carcinoma (HCC) to sorafenib. Here, we
European heart journal, 33(16), 2025-2034 (2012-06-20)
Cardiovascular disease is the most common cause of death in the world and atherosclerosis, an inflammatory process in the vessel wall, accounts for the majority of these deaths. The tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) has been shown to inhibit inflammation
3-Hydroxyanthranilic acid was identified in lymphocyte cultures during allogeneic stimulation. The metabolite and the synthetic product have identical HPLC retention times, fluorescence spectra, fluorescence intensities as a function of pH value and electrochemical behaviour.
Journal of child psychology and psychiatry, and allied disciplines, 51(8), 935-943 (2010-04-22)
Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
